Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Everolimus in Refractory Metastatic Colorectal Cancer With CDK12 Deficiency: A Prospective Multicenter Phase Ib/II Study (EVER-RECODE)

NCT07435584 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07435584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07435584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Everolimus in Refractory Metastatic Colorectal Cancer With CDK12 Deficiency: A Prospective Multicenter Phase Ib/II Study (EVER-RECODE)
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
December 31, 2028
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer